USANA Health Sciences (NYSE:USNA) Issues FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.450-2.450 for the period, compared to the consensus earnings per share estimate of 2.500. The company issued revenue guidance of $850.0 million-$850.0 million, compared to the consensus revenue estimate of $861.9 million.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

USANA Health Sciences Price Performance

Shares of NYSE:USNA traded up $0.02 on Friday, hitting $37.83. The company’s stock had a trading volume of 1,532 shares, compared to its average volume of 80,338. The company has a market capitalization of $720.66 million, a PE ratio of 13.36, a PEG ratio of 1.15 and a beta of 0.89. The company has a 50-day simple moving average of $37.96 and a 200 day simple moving average of $42.51. USANA Health Sciences has a 1 year low of $34.15 and a 1 year high of $54.81.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. The business had revenue of $200.22 million for the quarter, compared to the consensus estimate of $208.45 million. During the same period last year, the firm posted $0.59 earnings per share. On average, equities research analysts expect that USANA Health Sciences will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John Turman Fleming sold 1,000 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now directly owns 2,503 shares in the company, valued at $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,940 shares of company stock valued at $311,670. Insiders own 0.33% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.